Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Wuxi Apptec (药明康德) IPO: Pricing Update Before Book Close

Ascentage Pharma (亚盛医药) IPO: Too Early for an IPO

Wuxi Apptec (药明康德) IPO: What You Need to Know Before the Trading Debut

WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different

Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect

Smartkarma: ECM Coverage Weekly Update (7 July 2018)

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<p>Wuxi Apptec launched book building today with a price range of HKD 64.10 to HKD 71.50, planning to raise USD 954 million to USD 1,064 million. In this insight, we will recap our view, score the deal in our ECM framework and provide our final thought on the deal. </p>
<hr>
<h2>Our coverage on contract research companies</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/wuxi-apptec-ipo-this-a-h-listing-will-be-different" target="_blank">WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different</a></li>
<li><a href="https://www.smartkarma.com/insights/frontage-holding-ipo-more-disclosure-needed-to-understand-moat-and-growth-prospect" target="_blank">Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect</a></li>
</ul>
<h2>Our coverage on biotech listing</h2>
<ul>
<li><a href="https://www.smartkarma.com/insights/junshi-bioscience-ipo-early-in-application-but-behind-in-key-indications-part-1" target="_blank">Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/cansino-biologics-ipo-promising-pre-clinical-results-but-vaccine-scandal-weighs-part-1" target="_blank">CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/aobiome-therapeutics-ipo-hope-for-natural-therapeutic-treatment" target="_blank">AOBiome Therapeutics IPO: Hope for Natural Therapeutic Treatment</a></li>
<li><a href="https://www.smartkarma.com/insights/stealth-biotherapeutics-ipo-cure-the-symptoms-but-not-the-cause-part-1" target="_blank">Stealth Biotherapeutics IPO: Cure the Symptoms but Not the Cause (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/innovent-biologics-ipo-pricing-the-pd-1-and-biosimilars-competition-part-2" target="_blank">Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/innovent-biologics-ipo-a-major-pd-1-mab-competitor-might-have-just-emerged-part-1" target="_blank">Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)</a></li>
<li><a href="https://www.smartkarma.com/insights/micurx-pharma-ipo-betting-on-single-drug-in-the-not-so-attractive-antibiotic-segment" target="_blank">MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment</a></li>
<li><a href="https://www.smartkarma.com/insights/hua-medicine-ipo-thoughts-on-valuation" target="_blank">Hua Medicine (华领医药) IPO: Thoughts on Valuation</a></li>
<li><a href="https://www.smartkarma.com/insights/hua-medicine-ipo-reviving-roche-s-failed-attempt" target="_blank">Hua Medicine (华领医药) IPO: Reviving Roche’s Failed Attempt?</a></li>
<li><a href="https://www.smartkarma.com/insights/beigene-ipo-dual-listing-with-upside-capped-in-the-near-term" target="_blank">BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term</a></li>
<li><a href="https://www.smartkarma.com/insights/ascletis-pharma-ipo-valuation-not-justified-by-ganovo-and-ravidasvir-npv-part-3" target="_blank">Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)</a></li>
<li><a href="https://www.smartkarma.com/insights/ascletis-pharma-ipo-three-valuation-risk-factors-part-2" target="_blank">Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/ascletis-pharma-ipo-emerging-player-in-the-crowded-hcv-drug-market" target="_blank">Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market</a></li>
<li><a href="https://www.smartkarma.com/insights/china-isotope-radiation-ipo-oligopoly-visible-growth-and-high-barrier-to-entry" target="_blank">China Isotope &amp; Radiation IPO: Oligopoly, Visible Growth and High Barrier to Entry</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-ipo-thoughts-on-valuation-risks-and-upsides-part-2" target="_blank">Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)</a></li>
<li><a href="https://www.smartkarma.com/insights/zai-lab-ipo-experienced-team-promising-in-licensing-drug-pipeline-part-1" target="_blank">Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)</a></li>
</ul>

Wuxi Apptec launched book building today with a price range of HKD 64.10 to HKD 71.50, planning to raise USD 954 million to USD 1,064 million. In this insight, we will recap our view, score the deal in our ECM framework and provide our final thought on the deal. 

Our coverage on contract research companies

WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different
Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect

Our coverage on biotech listing

Junshi Bioscience (君实医药) IPO: Early in Application but Behind in Key Indications (Part 1)
CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)
AOBiome Therapeutics IPO: Hope for Natural Therapeutic Treatment
Stealth Biotherapeutics IPO: Cure the Symptoms but Not the Cause (Part 1)
Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)
Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)
MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment
Hua Medicine (华领医药) IPO: Thoughts on Valuation
Hua Medicine (华领医药) IPO: Reviving Roche’s Failed Attempt?
BeiGene (百济神州) IPO: Dual-Listing with Upside Capped in the Near Term
Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)
Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market
China Isotope &amp; Radiation IPO: Oligopoly, Visible Growth and High Barrier to Entry
Zai Lab IPO: Thoughts on Valuation, Risks and Upsides (Part 2)
Zai Lab IPO: Experienced Team, Promising In-Licensing Drug Pipeline (Part 1)


Hangzhou Tigermed Consulting (A) (300347 CH)

WuXi Apptec (药明康德) IPO:ミドルエンドとローエンドで上昇

WuXi AppTec

WuXi Apptec (药明康德) IPO:ミドルエンドとローエンドで上昇